Endometrial carcinoma · line 2 · Pembrolizumab + Lenvatinib (KEYNOTE-775) — 2L pMMR endometrial

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	2
Track	standard
Linked regimen	`REG-PEMBRO-LENVATINIB-ENDOM`

ID	`IND-ENDOMETRIAL-2L-PEMBRO-LENVA-PMMR`
Type	Indication
Status	reviewed 2026-04-26 \| pending_clinical_signoff
Diseases	`DIS-ENDOMETRIAL`
Sources	`SRC-ESMO-ENDOMETRIAL-2022` `SRC-NCCN-UTERINE-2025`

Notes

STUB — pending Co-Lead sign-off. Standard-track 2L for pMMR (NSMP / p53-abnormal HER2-negative) endometrial post-platinum. UA: not NSZU- reimbursed for endometrial 2L (2026); out-of-pocket / charitable. Single-agent doxorubicin or paclitaxel re-challenge is the realistic funded fallback.

Used By

Algorithms

ALGO-ENDOMETRIAL-2L - ALGO-ENDOMETRIAL-2L

Sources

SRC-GY018-MAKKER-2022 - Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer